Introduction: Inherited macrothrombocytopenia represents a heterogeneous
Introduction
Defined as a reduction in the number of platelets in the circulation, thrombocytopenia is usually an acquired disorder. However, defects in the genes regulating megakaryocyte differentiation and platelet production, which result in autosomal dominant or recessive, and X-linked forms of inherited thrombocytopenia, are increasingly being recognised [1] [2] [3] [4] [5] [6] . Thus, while previously considered to be a rare disorder, it is now thought that the frequency of inherited thrombocytopenia may be underestimated. The variable clinical expression of inherited thrombocytopenia may contribute to its under diagnosis since some patients are asymptomatic and the relatively mild bleeding symptoms in others can frequently be overlooked until a low platelet count is detected often as part of a routine blood test [7] . In contrast, patients with more severe forms of inherited thrombocytopenia are usually identified early in the perinatal period, or at times of haemostatic challenge.
Inherited macrothrombocytopenia, the most frequent form of inherited thrombocytopenia, represents a heterogeneous group of disorders characterised by a reduction in the number and an increase in the size of platelets. The molecular defects have been elucidated in a number of cases.
A significant proportion of patients have autosomal dominantly inherited MYH9-related disorders which are due to defects in MYH9 that disrupt the assembly or stability of the myosin complex and cause profound abnormalities in the platelet cytoskeleton that can also be associated nephritis, deafness and cataracts [2] .
In 2002, Naina et al. described a form of inherited thrombocytopenia which appeared to be highly prevalent among healthy blood donors in the NorthEastern states of the Indian subcontinent, affecting up to one third of healthy blood donors in West Bengal [5] . Termed Harris Platelet Syndrome (HPS), it was characterized by mild to severe macrothrombocytopenia, normal platelet function and an absence of inclusion bodies in the neutrophils. None of the donors had a history of excessive bleeding. Preliminary family studies suggested an autosomal dominant mode of inheritance and also that defects in MYH9 were not involved. In contrast, none of the randomly selected donors from Tamil Nadu in Southern India were found to have macrothrombocytopenia. The apparent absence of MYH9-RD in HPS suggests that the spectrum of molecular defects underlying macrothrombocytopenia in the West Bengal population differs from that observed in other well characterised cohorts of patients with inherited thrombocytopenia which, to date, have mainly been of European and Eastern origins. These findings also suggest that founder effects may contribute to the high prevalence of macrothrombocytopenia in the North
East, compared to the South of India.
In this study we have investigated the clinical expression and molecular basis of inherited macrothrombocytopenia in 112 index cases, the majority of whom originated from West Bengal and the North-Eastern states of India and
Nepal. Analysis of genes that have previously been associated with inherited macrothrombocytopenia identified candidate defects in 48 index cases leading us to conclude that inherited macrothrombocytopenia is a heterogeneous disorder in this population.
Materials and Methods

Study subjects and Methods
One hundred and twelve unrelated cases, who were referred to the Department of Haemostasis, National Institute of Immunohaematology,
Mumbai or the Department of Haematology, NRS Medical College, Kolkata for investigation of macrothrombocytopenia, were studied. Cases were enrolled in the study if they had a reduced platelet count (<150 X 10 9 /L) and a mean platelet volume (MPV) greater than 10fl which was associated with the presence of giant platelets as revealed by light microscopic examination of a peripheral blood smear. In some cases, the MPV was greater than 18.5fl
and could not be determined by the cell counter, but the presence of giant platelets was confirmed by examination of the peripheral blood smear.
All cases had normal anti-platelet antibody [8] , and ferritin levels, and were grouped according to whether they had mild (100-150 X 10 9 /L), moderate (50-100 X 10 9 /L) or severe (<50 X 10 9 /L) thrombocytopenia. A detailed clinical history, including age of onset and type of any bleeding symptoms was recorded for each case, using the World Health Organisation (WHO) bleeding scale (grade 0, no bleeding; grade 1, petechiae; grade 2, mild blood loss; grade 3, gross blood loss; grade 4, debilitating blood loss) to score the severity of bleeding symptoms. A family history of bleeding symptoms and information on consanguinity, were also obtained.
Candidate gene defects identified in the index cases were sought in genomic DNA from 100 healthy control subjects (Age Range: 10-65 years;
Male/Female: 52/48) all of whom had normal platelet counts (>200 X 10 9 /L), and MPV less than 10 fl and were also enrolled in the study.
The study was approved by the ethics committee and undertaken in accordance with the ethical guidance of the institution involved (No.
IIH/IEC/11-2007). Written, informed consent was obtained from all study subjects (cases and controls) prior to the collection of citrated and EDTA blood samples for phenotypic and genotypic analyses.
Laboratory Investigations
Coagulation tests to exclude a plasma factor deficiency included a Dade Dives-USA). All assays were carried out in a semi-automated coagulometer (Start 4, Diagnostica Stago, France) as described previously [9] . Full blood counts were determined on samples taken into EDTA using the XT-2000i cell counter (Transasia Bio-Medical Ltd, Mumbai, India) within 2 hours of collection. Peripheral blood smears were stained using modified
Leishman's stain and evaluated by light microscopy.
Platelet rich plasma (PRP) was prepared by centrifugation at 100g for 10 mins and in vitro platelet aggregation in response to ristocetin (0.5 and 1.25 mg/ml), adenosine diphosphate (ADP) (5µM), arachidonic acid (AA) (0.75mM) and collagen (2 µg/ml) was assessed using a lumi-aggregometer (Chronolog, Haverton, PA, USA 
Genotyping Studies
Genomic DNA was extracted from peripheral blood samples using a standard phenol-chloroform method and quantified using a NanodropTM1000 spectrophotometer (Thermo Scientific All the above online tools were accessed in December 2014.
Statistical Analysis
Data were analysed using INSTAT Graphpad analyser (graphpad.com/scientific-software/instat/) using Spearman's rank correlation method. P values <0.05 were considered significant [13] .
Results
Clinical and Phenotypic Features of the Index cases
The clinical features of the index cases are summarised in Table 2 . The cases comprised 55 females (median age 25 years; range 8-70 years) and 57 males (median age 30 years; range 8-70 years) ( Table 3 ). The geographic distribution of cases across India is shown in (Fig. 1 ). Of the cases, 68 (61%)
reported no history of bleeding symptoms (grade O), and 44 (39%) of the patients had bleeding manifestations; 6(5%) had grade 1 bleeding (petechiae), 18 (16%) had grade 2 bleeding (mild blood loss), 16 (14%) had grade 3 bleeding (gross blood loss) and only 4 (4%) patients reported grade 4 bleeding symptoms (debilitating blood loss). Predominant clinical manifestations were easy bruising 4 (4%), ecchymosis 8 (7%), epistaxis 18 (16%), frequent gum bleeding 6 (5%), menorrhagia 11 (10%) and a prolonged history of bleeding after trauma 7 (6%). One male, BM35.01, who had a history of frequent gum bleeds and two females who reported menorrhagia, BM78.01 & BM105.01, had previously required transfusions for excessive bleeding. Of the 68 asymptomatic cases, the majority of whom were identified incidentally during routine analysis of blood samples, 12 had a family history of bleeding and 3 had a personal history of transfusion in the past. There was no known consanguinity amongst the cases studied. The study of inheritance pattern in two index cases (BM15.01 & BM27.01) and their family members showed dominant mode of inheritance (Fig. 2) .
Examination of peripheral blood smears, which were available for all but one index case, BM46.01, confirmed the diagnosis of macrothrombocytopenia, and revealed the presence of stomatocytes in the red blood cells from 10 cases (Fig. 3) , and the absence of leukocyte inclusion bodies, in all cases.
There was a wide variation in platelet count among the cases; 45(40%) had mild thrombocytopenia, 54 (48%) had moderate thrombocytopenia, and 12 (11%) had severe thrombocytopenia which has resulted in their referral for investigation of bleeding problems. One patient had a normal platelet count but the peripheral blood smear revealed the presence of abnormally large platelets. The median MPV among the cases was 13.25 fl (range 12 -16.5fl).
The WHO bleeding score showed a significant inverse correlation with platelet count (P=0.016) and direct significant correlation with MPV (P=0.010) among the cases (Fig 3) .
The results of screening coagulation tests were within the normal ranges in all the cases. Platelet aggregation and receptor study showed reduced expression for cases with low platelet count to normal expression for cases with mild to moderate platelet count. (Table 4) .
In silico predictions of effects of candidate SNVs
Seventeen of the 20 novel missense changes identified in the study were predicted to be deleterious to protein function and stability (Table 5 ). Three SNVs, two predicting p.Leu176Arg and p.Gln76His substitutions in GPIX, and a third predicting a p.Glu1946Lys substitution in non-muscle myosin heavy chain 9 were predicted to have benign or borderline effects on protein function using two bioinformatic tools (PolyPhen and SIFT). However, all three of these alterations were also predicted to decrease the stability of the corresponding proteins using the MUPRO/I-Mutant 2.0 predictive tool (Table 5) .
Genotype-Phenotype Correlation
We examined the association between candidate gene defects and bleeding severity (as indicated by the WHO bleeding score) among those index cases who were heterozygous for recurrent candidate gene defects. (Table 2) .
No correlation could be established between mutations and phenotype in Bengal Macrothrombocytopenia cases (BM) ( Table 2) .
Discussion
Previous studies which have observed a high prevalence of a mild to severe form of non-MYH9 related macrothrombocytopenia among healthy blood donors in the north Eastern states of India, suggest that founder effects may contribute to the prevalence of macrothrombocytopenia in this geographic region. In this study, we have described the clinical expression of inherited macrothrombocytopenia in 112 index cases originating primarily from West
Bengal and the North-Eastern states of India and Nepal. The majority (61%) of the index cases were asymptomatic and were identified incidentally as a result of routine blood tests, while the remainder of the index cases reported symptoms consistent with the presence of a platelet bleeding disorder.
Analysis of a panel of genes which have been associated with inherited macrothrombocytopenia in other populations revealed candidate gene defects in 48 of the 112 (43%) index cases confirming the underlying heterogeneity of the macrothrombocytopenia in this population, with candidate gene defects being identified in GP1BA (n=4), GP1BB (n=3), GP9
(n=18), ABCG5 (n=12) and MYH9 (n=11).
Examination of peripheral blood smears was possible for all but one index case. Interestingly, none of the MYH9 gene defects identified in this study was associated with the presence of neutrophil inclusion bodies, and further work using immunofluorescent staining of non-muscle myosin would be required to determine whether the novel MYH9 defects identified in these patients are associated with abnormal distribution of myosin in peripheral blood neutrophils. Unfortunately, it was not possible to examine a peripheral blood smear from the index case who was heterozygous for the MYH9 nonsense variation, p.Arg1933* which we would expect to be associated with the presence of neutrophil inclusion bodies [14] . Of note, the MYH9 defects predicting the p.Asp1948Asn, p.Glu1946Lys alterations affected residues in the non-helical tail region of the myosin heavy chain defects in which have previously been reported to be associated with a milder bleeding diathesis The frequency of 2 SNVs in GP9; rs6069 (p.Thr44=), a synonymous change with minor allele frequency of 0.0583 and rs3796130 (p.Ala156Thr) with a minor allele frequency of 0.0675, were observed to be more prevalent in cases than in control subjects and were significantly associated with the disorder (Table   4 ). p.Ala156Thr was reported to be associated with low platelet count and also alters the protein function [30] and has a damaging effect on the protein stability as predicated by different tools (Table 5 ).
The identification of candidate defects in genes which have previously been associated with macrothrombocytopenia in 48 of the 112 cases studied here, lead us to conclude that inherited macrothrombocytopenia is a heterogeneous disorder in India. Further study will be required to identify the gene defects underlying macrothrombocytopenia in the remaining 64 (57%) cases without mutations in the genes investigated here.
Greater awareness of this condition will reduce the risk of misdiagnosis and the potential for inappropriate treatment of affected individuals which is important given that congenital macrothrombocytopenia is a common and under diagnosed condition in India [5, 31] . 
